Galera Therapeutics, Inc. financial data

Symbol
GRTX on OTC
Location
Malvern, PA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 792% % 37%
Debt-to-equity -103% % 9.1%
Return On Equity 6.1% % -58%
Return On Assets -125% % -13%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 75,462,390 shares
Common Stock, Shares, Outstanding 75,462,390 shares 39%
Entity Public Float $4,900,000 USD -96%
Common Stock, Value, Issued $75,000 USD 39%
Weighted Average Number of Shares Outstanding, Basic 98,503,430 shares 81%
Weighted Average Number of Shares Outstanding, Diluted 98,503,430 shares 81%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $235,000 USD -96%
General and Administrative Expense $5,922,000 USD -48%
Operating Income (Loss) $10,000,000 USD 50%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $1,388,000 USD 76%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $8,986,000 USD 54%
Earnings Per Share, Basic 0 USD/shares 59%
Earnings Per Share, Diluted 0 USD/shares 59%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $4,473,000 USD -47%
Assets, Current $4,901,000 USD -45%
Property, Plant and Equipment, Net $0 USD -100%
Operating Lease, Right-of-Use Asset $0 USD -100%
Goodwill $0 USD -100%
Other Assets, Noncurrent $101,000 USD 4950%
Assets $5,002,000 USD -44%
Accounts Payable, Current $434,000 USD 47%
Accrued Liabilities, Current $164,000 USD -73%
Liabilities, Current $598,000 USD -35%
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $151,647,000 USD -0.21%
Retained Earnings (Accumulated Deficit) $460,418,000 USD -2%
Stockholders' Equity Attributable to Parent $149,222,000 USD -4.3%
Liabilities and Equity $5,002,000 USD -44%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $2,238,000 USD 53%
Net Cash Provided by (Used in) Financing Activities $635,000 USD
Net Cash Provided by (Used in) Investing Activities $0 USD -100%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 75,462,390 shares 39%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,603,000 USD 67%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4,473,000 USD -47%
Deferred Tax Assets, Valuation Allowance $75,754,000 USD 4%
Deferred Tax Assets, Gross $75,952,000 USD 3.1%
Operating Lease, Liability $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $18,957,000 USD 68%
Lessee, Operating Lease, Liability, to be Paid $1,401,000 USD -12%
Property, Plant and Equipment, Gross $0 USD -100%
Operating Lease, Liability, Current $0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two $220,000 USD 1.4%
Lessee, Operating Lease, Liability, to be Paid, Year One $217,000 USD 11%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $207,000 USD -24%
Lessee, Operating Lease, Liability, to be Paid, Year Three $224,000 USD 1.8%
Deferred Tax Assets, Operating Loss Carryforwards $52,962,000 USD 8.2%
Preferred Stock, Shares Issued 119,318 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $633,000 USD -26%
Operating Lease, Payments $3,000 USD -94%
Preferred Stock, Shares Outstanding 119,318 shares
Depreciation, Depletion and Amortization $0 USD -100%
Deferred Tax Assets, Net of Valuation Allowance $198,000 USD -75%
Share-based Payment Arrangement, Expense $714,000 USD -79%
Interest Expense $0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%